EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid‐19

Inès Ben Ghezala iD, Nathan Peiffer-Smadja iD, Caroline Solas iD, Antoine Nougairède iD, Franck Touret iD, Marc Bardou iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70505 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Inès Ben Ghezala und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, CIC 1432, Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, University Hospital, Dijon, France. Hauptthemen laut MEDLINE: Antiviral Agents, Drug Repositioning, COVID-19 Drug Treatment. Die Arbeit nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Covid‐19 pandemic highlighted the urgent need for effective therapies against emerging pathogens. Drug repurposing, defined as the use of existing medications for new therapeutic purposes, was extensively pursued for SARS‐CoV‐2 but has not yielded successful treatments. This narrative review critically examines the pharmacological and methodological factors that contributed to these unsuccessful outcomes, paying particular attention to tests of azithromycin and hydroxychloroquine. There are many reasons the promise of repurposed drugs was not realized. Many repurposed compounds displayed promising in vitro antiviral activity that did not translate into clinical efficacy. Major pharmacokinetic (PK) limitations, for example, poor oral bioavailability, low concentrations in pulmonary tissue, and extensive plasma protein binding, prevented these drugs from reaching therapeutic levels in humans. Preclinical research often relied on non‐human cell lines and animal models that inadequately reflected human physiology, leading to misleading experimental outcomes. Clinical trials were often undermined by methodological limitations, including endpoints with uncertain clinical significance, suboptimal comparators, and insufficient attention paid to key PK and pharmacodynamic (PD) parameters such as half maximal effective concentration (EC50) values. This narrative review emphasizes the importance of integrating comprehensive PK/PD assessments, relevant experimental models, and rigorous trial design to strengthen drug development during future health crises. The relative success of antivirals including molnupiravir, nirmatrelvir, and remdesivir, which were either novel or previously unapproved compounds, suggests the value of designing and developing targeted antivirals. We must coordinate global research, develop pharmacologically sound strategies, and use evidence‐based decision‐making to effectively prepare for future pandemics and quickly produce effective treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDrug RepositioningCOVID-19 Drug TreatmentHumansAnimalsSARS-CoV-2COVID-19PandemicsHydroxychloroquineClinical Trials as TopicAzithromycinAdenosine Monophosphate

Stichwörter der Autor:innen

anti‐infectiveclinical trialsdrug developmentefficacyin vitroin vivoinfectious diseasepharmacodynamicspharmacokineticspreclinical

Substanzen

Antiviral AgentsHydroxychloroquineAzithromycinAdenosine Monophosphate

Autor:innen und Institutionen

  • Inserm, CIC 1432, Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, University Hospital, Dijon, France.
  • Université Paris Cité et Université Sorbonne Paris Nord, Paris, France.
  • Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Paris, France.
  • Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
  • Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, APHM, Marseille, France.

ORCID-Profile: Inès Ben Ghezala, Nathan Peiffer-Smadja, Caroline Solas, Antoine Nougairède, Franck Touret, Marc Bardou

Zitieren

APA

Ben Ghezala, I., Peiffer-Smadja, N., Solas, C., Nougairède, A., Touret, F., & Bardou, M. (2026). How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid‐19. Clinical and Translational Science. https://doi.org/10.1111/cts.70505

Vancouver

Ben Ghezala I, Peiffer-Smadja N, Solas C, Nougairède A, Touret F, Bardou M. How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid‐19. Clinical and Translational Science. 2026. doi:10.1111/cts.70505

BibTeX
@article{BenGhezala2026,
  author = {Ben Ghezala, Inès and Peiffer-Smadja, Nathan and Solas, Caroline and Nougairède, Antoine and Touret, Franck and Bardou, Marc},
  title = {How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid‐19},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70505}
}
Kostenlos starten →